Biocompatibles CE-marks embolisation beads:
This article was originally published in Clinica
Biocompatibles International has CE-marked for sale in Europe its Bead Block embolisation therapy for preventing blood flow to a tumour. The microspheres-based product can provide a minimally invasive alternative to hysterectomy in the treatment of uterine fibroids, says the UK firm. It may also provide a platform for targeted drug delivery. The Farnham, Surrey company has initiated a programme for drug-eluting embolics based on the product which will initially target malignant tumours, such as liver cancer. Bead Block is to be distributed exclusively by Terumo in Europe, Israel and North Africa. It is already approved in the US, where Biocompatibles is seeking approval for the uterine fibroid indication.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.